Language Interpretation Solutions for Breast Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests different methods of providing language interpretation services for breast cancer patients who primarily speak Spanish or Mandarin and have limited English proficiency. It seeks to identify the best method among three options: remote consecutive medical interpreting (RCMI, done after the speaker pauses), remote consecutive video medical interpreting (RCVI), and remote simultaneous medical interpreting (RSMI, done in real-time). The trial seeks patients with Stage II or III breast cancer who are visiting their medical oncologist for the first or second time. As an unphased trial, this study offers a unique opportunity to enhance communication and care for non-English speaking patients.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that these language interpretation solutions are safe for breast cancer patients with limited English proficiency?
Research has shown that remote medical interpreting methods, such as Remote Consecutive Medical Interpreting (RCMI), Remote Consecutive Video Medical Interpreting (RCVI), and Remote Simultaneous Medical Interpreting (RSMI), are generally well-received by patients. Studies have examined their ability to improve communication without compromising safety. The available research does not report any specific negative effects associated with these methods. They serve as a safe and accurate alternative to traditional in-person interpreting, without introducing new safety concerns. This indicates that participants in these trials are not exposed to additional risks from the interpreting methods being tested.12345
Why are researchers excited about this trial?
Researchers are excited about this trial because it's exploring innovative language interpretation methods for breast cancer patients who have limited English proficiency (LEP). Unlike traditional interpreters who are physically present, the trial is testing remote interpreting solutions, including Remote Consecutive Medical Interpreting (RCMI), Remote Consecutive Video Medical Interpreting (RCVI), and Remote Simultaneous Medical Interpreting (RSMI). These methods aim to provide more accessible, flexible, and potentially cost-effective communication between non-English-speaking patients and their healthcare providers. By evaluating these remote solutions, the trial hopes to identify effective ways to improve patient understanding and participation in their treatment plans, ultimately enhancing their overall healthcare experience.
What evidence suggests that this trial's language interpretation solutions could be effective for breast cancer patients with limited English proficiency?
Research has shown that remote medical interpreters can greatly improve patient care, especially for those who have difficulty with English. This trial will compare different remote interpreting methods. Participants may receive Remote Simultaneous Medical Interpreting (RSMI), which studies indicate often leads to fewer medical mistakes and is quicker than other methods. Other participants will receive Remote Consecutive Medical Interpreting (RCMI) or Remote Consecutive Video Medical Interpreting (RCVI), both of which also improve communication between patients and healthcare providers, reducing language barriers. Overall, these methods effectively enhance healthcare experiences for patients who are not fluent in English.12467
Who Is on the Research Team?
Francesca Gany, MD, MPH
Principal Investigator
Memorial Sloan Kettering Cancer Center
Are You a Good Fit for This Trial?
This trial is for Spanish and Mandarin-speaking breast cancer patients with limited English proficiency, specifically those in stages II and III of the disease. They will be working with English-speaking healthcare providers who do not speak Spanish or Mandarin.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Phase 1: Treatment
3-arm randomized controlled trial of Remote Simultaneous Medical Interpreting (RSMI), Remote Consecutive Medical Interpreting (RCMI), and Remote Consecutive Video Medical Interpreting (RCVI) in breast cancer outpatient clinical encounters
Phase 2: Evaluation
Sequential mixed-methods explanatory, multi-stakeholder process evaluation to gather implementation potential data
Follow-up
Participants are monitored for interpretation errors and implementation potential
What Are the Treatments Tested in This Trial?
Interventions
- Remote Consecutive Medical Interpreting/RCMI
- Remote Consecutive Video Medical Interpreting/RCVI
- Remote Simultaneous Medical Interpreting/RSMI
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor